Disselhorst Maria M J, Burgers Sjaak J A, Baas Paul
Department of Thoracic Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.
Curr Treat Options Oncol. 2017 Aug;18(8):48. doi: 10.1007/s11864-017-0488-7.
The optimal treatment of patients with advanced malignant pleural mesothelioma (MPM) has not yet been discovered. With the aid of an increased insight in the molecular pathways and the development of combinations of Immuno-Oncology (IO), drugs new therapies are available. The personalization of treatment by cell cultures and pathway analysis attracts more attention nowadays. It is conceivable that in the near future the treatment of patients with MPM will consist of a combination of IO drugs or specific pathway inhibitors.
晚期恶性胸膜间皮瘤(MPM)患者的最佳治疗方法尚未找到。随着对分子途径的深入了解以及免疫肿瘤学(IO)药物组合的发展,新的治疗方法已经出现。如今,通过细胞培养和途径分析进行个性化治疗越来越受到关注。可以想象,在不久的将来,MPM患者的治疗将由IO药物或特定途径抑制剂的组合组成。